IMNM Insider Trading

Insider Ownership Percentage: 8.60%
Insider Buying (Last 12 Months): $2,265,265.18
Insider Selling (Last 12 Months): $279,313.12

Immunome Insider Trading History Chart

This chart shows the insider buying and selling history at Immunome by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$1.16Mbought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M-$500k$0$500k$1MTotal Insider BuyingTotal Insider Selling

Immunome Share Price & Price History

Current Price: $8.93
Price Change: Price Decrease of -0.28 (-3.04%)
As of 03/13/2025 05:00 PM ET

This chart shows the closing price history over time for IMNM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
AprMayJunJulAugSepOctNovDecJanFebMar$8.93Closing price on 03/13/25:

SEC Filings (Institutional Ownership Changes) for Immunome (NASDAQ:IMNM)

44.58% of Immunome stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at IMNM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$61Mbought$12MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$60M-$40M-$20M$0$20M$40M$60MTotal InflowsTotal Outflows
Immunome logo
Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Read More on Immunome

Today's Range

Now: $8.93
Low: $8.87
High: $9.49

50 Day Range

MA: $10.06
Low: $8.73
High: $11.83

52 Week Range

Now: $8.93
Low: $8.39
High: $26.70

Volume

494,077 shs

Average Volume

905,366 shs

Market Capitalization

$712.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.93

Who are the company insiders with the largest holdings of Immunome?

Immunome's top insider shareholders include:
  1. Clay B Siegall (CEO)
  2. Max Rosett (CFO)
  3. Bruce Turner (Insider)
  4. Philip Tsai (CTO)
  5. Jean Jacques Bienaime (Director)
  6. Jack Higgins (Insider)
  7. Robert Lechleider (Insider)
Learn More about top insider investors at Immunome.

Who are the major institutional investors of Immunome?

Immunome's top institutional investors include:
  1. T. Rowe Price Investment Management Inc. — 6.89%
  2. Redmile Group LLC — 6.05%
  3. Enavate Sciences GP LLC — 4.36%
  4. Janus Henderson Group PLC — 4.33%
  5. Vanguard Group Inc. — 3.76%
  6. Price T Rowe Associates Inc. MD — 2.86%
Learn More about top institutional investors of Immunome stock.

Which institutional investors are selling Immunome stock?

During the previous quarter, IMNM stock was sold by these institutional investors:
  1. Invesco Ltd.
  2. T. Rowe Price Investment Management Inc.
  3. Marshall Wace LLP
  4. Vanguard Group Inc.
  5. Redmile Group LLC
  6. Bank of America Corp DE
  7. Jane Street Group LLC
  8. Janus Henderson Group PLC
During the previous year, company insiders that have sold Immunome company stock include:
  1. Clay B Siegall (CEO)
  2. Max Rosett (CFO)
Learn More investors selling Immunome stock.

Which institutional investors are buying Immunome stock?

Within the previous quarter, IMNM stock was bought by institutional investors including:
  1. Enavate Sciences GP LLC
  2. JPMorgan Chase & Co.
  3. Granahan Investment Management LLC
  4. Renaissance Technologies LLC
  5. Adage Capital Partners GP L.L.C.
  6. Price T Rowe Associates Inc. MD
  7. Point72 Asset Management L.P.
  8. Millennium Management LLC
During the previous year, these company insiders have bought Immunome stock:
  1. Clay B Siegall (CEO)
  2. Max Rosett (CFO)
  3. Bruce Turner (Insider)
  4. Philip Tsai (CTO)
  5. Jean Jacques Bienaime (Director)
Learn More investors buying Immunome stock.